• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

    1.050 -0.060 (-5.41%)
    Streaming Delayed Price Updated: 12:26 PM EST, Jan 8, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 706,541
    Open 1.110
    Bid (Size) 1.050 (7,900)
    Ask (Size) 1.060 (7,000)
    Prev. Close 1.110
    Today's Range 1.050 - 1.115
    52wk Range 0.6611 - 1.940
    Shares Outstanding 98,384,456
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs
    From Fate Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +6.4%
    +6.4%
    1 Month
    -1.9%
    -1.9%
    3 Month
    -30.5%
    -30.5%
    6 Month
    -8.7%
    -8.7%
    1 Year
    -40.0%
    -40.0%

    More News

    Read More
    News headline image
    Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Adaptimmune Plunges After Announcing Nasdaq Delisting Amidst Compliance Failures and Cost-Cutting Measures
    Via MarketMinute
    Topics Initial Public Offering Regulatory Compliance Workforce
    News headline image
    Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
    Via Benzinga
    News headline image
    Fate Therapeutics to Present at Upcoming Investor Conferences
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    FATE THERAPEUTICS INC (NASDAQ:FATE) Reports Mixed Q2 2025 Results with Revenue Beat and Narrower Loss ↗
    Via Chartmill
    News headline image
    Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4 Analysts Assess Fate Therapeutics: What You Need To Know ↗
    Via Benzinga
    News headline image
    Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Gapping stocks in Monday's session ↗
    Via Chartmill
    News headline image
    Fate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays Optimistic ↗
    Via Stocktwits

    Frequently Asked Questions

    Is Fate Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Fate Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Fate Therapeutics, Inc. - Common Stock trade on?
    Fate Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Fate Therapeutics, Inc. - Common Stock?
    The ticker symbol for Fate Therapeutics, Inc. - Common Stock is FATE on the Nasdaq Stock Market
    What is the current price of Fate Therapeutics, Inc. - Common Stock?
    The current price of Fate Therapeutics, Inc. - Common Stock is 1.050
    When was Fate Therapeutics, Inc. - Common Stock last traded?
    The last trade of Fate Therapeutics, Inc. - Common Stock was at 01/08/26 12:26 PM ET
    What is the market capitalization of Fate Therapeutics, Inc. - Common Stock?
    The market capitalization of Fate Therapeutics, Inc. - Common Stock is 103.30M
    How many shares of Fate Therapeutics, Inc. - Common Stock are outstanding?
    Fate Therapeutics, Inc. - Common Stock has 103M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.